कनाडा - फ़्रेंच - Health Canada

sanis health inc - imatinib (mésylate d'imatinib) - comprimé - 100mg - imatinib (mésylate d'imatinib) 100mg - antineoplastic agents

कनाडा - फ़्रेंच - Health Canada

sanis health inc - imatinib (mésylate d'imatinib) - comprimé - 400mg - imatinib (mésylate d'imatinib) 400mg - antineoplastic agents

स्विट्ज़रलैंड - फ़्रेंच - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - imatinibum - filmtalbetten - imatinibum 100 mg à imatinibi mesilas, cellulosum microcristallinum, crospovidonum, hypromellosum, de la silice colloidalis anhydrica, magnésium stearas, Überzug: macrogolum 4000, talc, hypromellosum, e 172 (rouge) e 172 (jaune), pour compresso de la brume. - onkologikum - synthetika

स्विट्ज़रलैंड - फ़्रेंच - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - imatinibum - filmtalbetten - imatinibum 400 mg à imatinibi mesilas, cellulosum microcristallinum, crospovidonum, hypromellosum, de la silice colloidalis anhydrica, magnésium stearas, Überzug: macrogolum 4000, talc, hypromellosum, e 172 (rouge) e 172 (jaune), pour compresso de la brume. - onkologikum - synthetika

बेल्जियम - फ़्रेंच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

joint stock company grindeks - mésilate d'imatinib 119,5 mg - eq. imatinib 100 mg - gélule - 100 mg - mésilate d'imatinib 119.5 mg - imatinib

यूरोपीय संघ - फ़्रेंच - EMA (European Medicines Agency)

koanaa healthcare gmbh - l'imatinib mésilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - agents antinéoplasiques - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. les patients qui ont une faible ou très faible risque de récidive ne doit pas recevoir de traitement adjuvant. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. sauf dans les pays nouvellement diagnostiqué en phase chronique de la lmc, il n'y a pas d'essais contrôlés à démontrer un bénéfice clinique ou l'augmentation de la survie pour ces maladies.

कनाडा - फ़्रेंच - Health Canada

sivem pharmaceuticals ulc - imatinib (mésylate d'imatinib) - comprimé - 100mg - imatinib (mésylate d'imatinib) 100mg - antineoplastic agents

कनाडा - फ़्रेंच - Health Canada

sivem pharmaceuticals ulc - imatinib (mésylate d'imatinib) - comprimé - 400mg - imatinib (mésylate d'imatinib) 400mg - antineoplastic agents

बेल्जियम - फ़्रेंच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo pharma b.v. - mésilate d'imatinib 119,47 mg - eq. imatinib 100 mg - comprimé pelliculé - imatinib

बेल्जियम - फ़्रेंच - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - mésilate d'imatinib 477,88 mg - eq. imatinib 400 mg - comprimé pelliculé - imatinib